The Current Scientific and Legal Status of Alternative Methods to the LD50 Test for Botulinum Neurotoxin Potency Testing

Council of Europe (2006). Botulinum Toxin Type A for Injection 01/2005:2113. In European Pharmacopoeia 6.0, pp. 1117–1119. Strasbourg, France: Council of Europe.

Simpson L.L. (1981). The origin, structure, and pharmacological activity of botulinum toxin. Pharmacological Reviews 33, 155–188.

Lacy D.B. & Stevens R.C. (1997). Recombinant expression and purification of the botulinum neurotoxin type A translocation domain. Protein Expression & Purification 11, 195–200.

Hanson M.A. & Stevens R.C. (2000). Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0Å resolution. Nature Structural Biology 7, 687–692.

Simpson L.L. (1980). Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. Journal of Pharmacology & Experimental Therapeutics 212, 16–21.

Dolly J.O. , Black J. , Williams R.S. & Melling J. (1984). Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature, London 307, 457–460.

Simpson L.L. (1986). Molecular pharmacology of botulinum toxin and tetanus toxin. Annual Review of Pharmacology & Toxicology 26, 427–453.

Black J.D. & Dolly J.O. (1986). Interaction of ¹²⁵I-labeled botulinum neurotoxins with nerve terminals. II: Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. Journal of Cell Biology 103, 535–544.

Schiavo G. , Rossetto O. , Santucci A. , DasGupta B.R. & Montecucco C. (1992). Botulinum neurotoxins are zinc proteins. Journal of Biological Chemistry 267, 23,479–23,483.

Schiavo G. , Matteoli M. & Montecucco C. (2000). Neurotoxins affecting neuroexocytosis. Physiological Reviews 80, 717–766.

Anon. (1986). Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes. Official Journal of the European Communities L358, 18/12/1986, 1–28. Available at: http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celex-plus!prod!DocNumber&lg=en&type_doc=Directive&an_doc=86&nu_doc=609 (Accessed 22.06.10).

Anon. (2001). Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Official Journal of the European Communities L311, 28/11/2001, 67–128. Available at: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32001L0083:EN:NOT (Accessed 24.06.10).

Anon. (1996). Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Communities L136, 30/04/2004, 34–57. Available at: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2004:136:0034:0057:EN:PDF (Accessed 05.05.10).

Anon. (2009). Botulinum toxin type A for injection. Pharmeuropa 21.3, 361–363.

Anon. (2009). Botulinum toxin type B for injection. Pharmeuropa 21.3, 363–365.

FDA (undated). The Code of Federal Regulations. Title 21 — Food and Drugs. Chapter I — Food and Drug Administration, Department of Health and Human Services. (4-1-10 Edition). Available at: http://www.access.gpo.gov/nara/cfr/waisidx_10/21cfrv1_10.html (Accessed 10.08.10).

ICH (1996). ICH Harmonised Tripartite Guideline. Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products, Q5C, 10pp. Geneva, Switzerland: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Available at: http://www.ich.org/LOB/media/MEDIA427.pdf (Accessed 24.06.10).

ICH (2005). ICH Harmonised Tripartite Guideline. Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process, Q5E, 16pp. Geneva, Switzerland: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Available at: http://www.ich.org/LOB/media/MEDIA1196.pdf (Accessed 24.06.10).

ICH (1994). ICH Harmonised Tripartite Guideline. Validation of Analytical Procedures: Text and Methodology, Q2(R1), 17pp. Geneva, Switzerland: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Available at: http://www.ich.org/LOB/media/MEDIA417.pdf (Accessed 24.06.10).

McLellan K. , Das R.E. , Ekong T.A. & Sesardic D. (1996). Therapeutic botulinum type A toxin: Factors affecting potency. Toxicon: Official Journal of the International Society on Toxinology 34, 975–985.

Sesardic D. , Leung T. & Gaines Das R.E. (2003). Role for standards in assays of botulinum toxins: International collaborative study of three preparations of botulinum type A toxin. Biologicals 31, 265–276.

OECD (2001). OECD Guideline for the Testing of Chemicals. No. 420. Acute Oral Toxicity: Fixed Dose Procedure, 14pp. Paris, France: Organisation for Economic Co-operation and Development. Available at: http://lysander.sourceoecd.org/vl=942322/cl=12/nw=1/rpsv/cw/vhosts/oecdjournals/1607310x/v1n4/contp1-1.htm (Accessed 24.06.10).

Sesardic D. , McLellan K. , Ekong T.A.N. & Gaines Das R. (1996). Refinement and validation of an alternative bioassay for potency testing of therapeutic botulinum type A toxin. Pharmacology & Toxicology 78, 283–288.

Pickett A. , O'Keeffe R. , Judge A. & Dodd S. (2008). The in vivo rat muscle force model is a reliable and clinically relevant test of consistency among botulinum toxin preparations. Toxicon: Official Journal of the International Society on Toxinology 52, 455–464.

Aoki K.R. (2001). A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon: Official Journal of the International Society on Toxinology 39, 1815–1820.

Aoki K.R. (2002). Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon: Official Journal of the International Society on Toxinology 40, 923–928.

Sesardic D. & Gaines Das R.E. (2009). Botulinum toxin: Applying the 3Rs to product potency testing, 8pp. London, UK: NC3Rs. Available at: http://www.nc3rs.org.uk/downloaddoc.asp?id=853&page=1023&skin=0 (Accessed 24.06.10).

Wohlfarth K. , Göschel H. , Frevert J. , Dengler R. & Bigalke H. (1997). Botulinum A toxins: Units versus units. Naunyn-Schmiedeberg's Archives of Pharmacology 355, 335–340.

Rasetti-Escargueil C. , Jones R.G. , Liu Y. & Sesardic D. (2009). Measurement of botulinum types A, B and E neurotoxicity using the phrenic nerve-hemidiaphragm: Improved precision with inbred mice. Toxicon: Official Journal of the International Society on Toxinology 53, 503–511.

Huber A. , France R.M. , Riccalton-Banks L. , McLaren J. , Cox H. , Quirk R.A. , Shakesheff K.M. , Thompson D. , Panjwani N. , Shipley S. & Pickett A. (2008). The Intercostal NMJ Assay — A new alternative to the conventional LD50 assay for the determination of the therapeutic potency of botulinum toxin preparations. ATLA 36, 141–152.

Pellett S. , Tepp W.H. , Clancy C.M. , Borodic G.E. & Johnson E.A. (2007). A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Letters 581, 4803–4808.

Podrygajlo G. , Tegenge M.A. , Gierse A. , Paquet-Durand F. , Tan S. , Bicker G. & Stern M. (2009). Cellular phenotypes of human model neurons (NT2) after differentiation in aggregate culture. Cell & Tissue Research 336, 439–452.

Paquet-Durand F. & Bicker G. (2007). Human model neurons in studies of brain cell damage and neural repair. Current Molecular Medicine 7, 541–554.

Podrygajlo G. , Song Y. , Schlesinger F. , Krampfl K. & Bicker G. (2010). Synaptic currents and transmitter responses in human NT2 neurons differentiated in aggregate culture. Neuroscience Letters 468, 207–210.

Ekong T.A. , Feavers I.M. & Sesardic D. (1997). Recombinant SNAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro. Microbiology 143, 3337–3347.

Sesardic D. , Jones R.G. , Leung T. , Alsop T. & Tierney R. (2004). Detection of antibodies against botulinum toxins. Movement Disorders: Official Journal of the Movement Disorder Society 19, Suppl. 8, S85–S91.

Gaines Das R.E. , Heath A.B. , Martin H. & Sesardic D. (1999). Validation of in vitro assays for botulinum toxin: a case study. Developments in Biological Standardization 101, 267–276.

Jones R.G.A. , Ochiai M. , Liu Y. , Ekong T. & Sesardic D. (2008). Development of improved SNAP25 endopeptidase immune-assays for botulinum type A and E toxins. Journal of Immunological Methods 329, 92–101.